Edition:
United Kingdom

Gilead Sciences Inc (GILD.OQ)

GILD.OQ on NASDAQ Stock Exchange Global Select Market

68.25USD
23 Jan 2019
Change (% chg)

$-0.30 (-0.44%)
Prev Close
$68.55
Open
$68.52
Day's High
$69.50
Day's Low
$67.83
Volume
1,985,142
Avg. Vol
2,728,365
52-wk High
$89.53
52-wk Low
$60.32

Latest Key Developments (Source: Significant Developments)

Gilead Sciences Names Daniel O’Day Chairman And Chief Executive Officer
Monday, 10 Dec 2018 

Dec 10 (Reuters) - Gilead Sciences Inc ::GILEAD SCIENCES NAMES DANIEL O’DAY CHAIRMAN AND CHIEF EXECUTIVE OFFICER.APPOINTED GREGG ALTON AS INTERIM CHIEF EXECUTIVE OFFICER FOR PERIOD OF JANUARY 1, 2019 UNTIL O'DAY'S START DATE OF MARCH 1, 2019.APPOINTMENT OF DANIEL O'DAY AS CHAIRMAN OF BOARD AND CHIEF EXECUTIVE OFFICER IS EFFECTIVE MARCH 1, 2019.  Full Article

Target PharmaSolutions Collaborates With Gilead On NASH, Hep B Research
Tuesday, 20 Nov 2018 

Nov 20 (Reuters) - TARGET PharmaSolutions Inc::TARGET PHARMASOLUTIONS TO ADVANCE RESEARCH IN NASH AND HEPATITIS B THROUGH NEW COLLABORATION WITH GILEAD SCIENCES.TARGET PHARMASOLUTIONS SAYS GILEAD IS 6TH PARTNER IN TARGET-NASH, JOINING ALLERGAN, BOEHRINGER INGELHEIM, BRISTOL-MYERS SQUIBB, INTERCEPT AND NOVARTIS.  Full Article

Gilead Sciences Says China NMPA Approves Vemlidy For Chronic Hepatitis B Virus Infection
Monday, 19 Nov 2018 

Nov 18 (Reuters) - Gilead Sciences Inc ::GILEAD SCIENCES SAYS CHINA NMPA APPROVES GILEAD'S VEMLIDY (TENOFOVIR ALAFENAMIDE) FOR CHRONIC HEPATITIS B VIRUS (HBV) INFECTION.  Full Article

Gilead Announces Positive Phase 2 Results For Gs-9674 In Primary Sclerosing Cholangitis
Friday, 9 Nov 2018 

Nov 9 (Reuters) - Gilead Sciences Inc ::GILEAD ANNOUNCES POSITIVE PHASE 2 RESULTS FOR GS-9674 IN PRIMARY SCLEROSING CHOLANGITIS (PSC) AT THE LIVER MEETING® 2018.GILEAD SCIENCES INC - GS-9674 GRANTED ORPHAN DRUG DESIGNATION BY U.S. FOOD AND DRUG ADMINISTRATION.GILEAD SCIENCES INC - GS-9674 WAS WELL TOLERATED.GILEAD SCIENCES INC - GS-9674 WAS WELL TOLERATED.GILEAD SCIENCES INC - TREATMENT WAS DISCONTINUED DUE TO ADVERSE EVENTS IN THREE PATIENTS TREATED WITH GS-9674 100 MG.GILEAD SCIENCES INC - ONE DISCONTINUATION DUE TO PRURITUS, AND ONE PATIENT WITH PLACEBO IN TRIAL.  Full Article

Gilead Sciences, Tango Therapeutics Announce Strategic Collaboration
Wednesday, 31 Oct 2018 

Oct 31 (Reuters) - Gilead Sciences Inc ::GILEAD SCIENCES AND TANGO THERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP NEXT-GENERATION TARGETED IMMUNO-ONCOLOGY THERAPIES.GILEAD SCIENCES SAYS TANGO WILL RECEIVE UPFRONT PAYMENT OF $50 MILLION UNDER TERMS OF DEAL.GILEAD SCIENCES SAYS TANGO WILL ALSO BE ELIGIBLE TO RECEIVE ABOUT $1.7 BILLION IN ADDITIONAL PAYMENTS ACROSS PROGRAMS.GILEAD SCIENCES SAYS TANGO WILL ALSO BE ELIGIBLE TO RECEIVE UP TO LOW DOUBLE-DIGIT TIERED ROYALTIES ON NET SALES UNDER TERMS OF DEAL.GILEAD SCIENCES SAYS FOR PROGRAMS TANGO OPTS TO CO-DEVELOP & CO-DETAIL, PARTIES WILL SPLIT PROFITS & LOSSES 50/50 FOR U.S..GILEAD SCIENCES - FOR PROGRAMS TANGO OPTS TO CO-DEVELOP & CO-DETAIL, TANGO WILL BE ELIGIBLE TO RECEIVE MILESTONE PAYMENTS & ROYALTIES ON EX-U.S. SALES.GILEAD SCIENCES SAYS UNDER MULTI-YEAR COLLABORATION, TANGO WILL PERFORM TARGET DISCOVERY & VALIDATION.GILEAD SCIENCES SAYS WILL HAVE OPTIONS TO WORLDWIDE RIGHTS ON UP TO 5 TARGETS FROM TANGO’S PROPRIETARY FUNCTIONAL GENOMICS-BASED DISCOVERY PLATFORM.GILEAD SCIENCES SAYS COLLABORATION DOES NOT INCLUDE TANGO’S LEAD PROGRAMS, FOR WHICH TANGO WILL RETAIN ALL RIGHTS.  Full Article

Gilead Sciences Announces Fourth Quarter 2018 Dividend
Thursday, 25 Oct 2018 

Oct 25 (Reuters) - Gilead Sciences Inc ::GILEAD SCIENCES ANNOUNCES FOURTH QUARTER 2018 DIVIDEND.GILEAD SCIENCES INC - DECLARED A CASH DIVIDEND OF $0.57 PER SHARE OF COMMON STOCK FOR Q4 OF 2018.  Full Article

Gilead Sciences Inc - Quarterly Diluted Earnings Per Share $1.60
Thursday, 25 Oct 2018 

Oct 25 (Reuters) - Gilead Sciences Inc ::QTRLY TOTAL REVENUE $5,596 MILLION VERSUS $6,512 MILLION.QTRLY DILUTED EARNINGS PER SHARE$1.60.QTRLY NON-GAAPDILUTED EARNINGS PER SHARE $1.84.TOTAL PRODUCT SALES FOR Q3 OF 2018 WERE $5.5 BILLION COMPARED TO $6.4 BILLION FOR SAME PERIOD IN 2017.REVISED FULL YEAR 2018 GUIDANCE.SEES 2018 NET PRODUCT SALES $20,800 MILLION - $21,300 MILLION.GILEAD SCIENCES-SEES 2018 DILUTED EPS IMPACT OF ACQUISITION-RELATED, UP-FRONT COLLABORATION, STOCK-BASED COMPENSATION AND OTHER EXPENSES $1.50 - $1.60.QTRLY TOTAL HARVONI SALES $311 MILLION VERSUS $973 MILLION.Q3 EARNINGS PER SHARE VIEW $1.63, REVENUE VIEW $5.38 BILLION -- THOMSON REUTERS I/B/E/S.FY2018 REVENUE VIEW $21.43 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Gilead Subsidiary To Launch Authorized Generics Of Epclusa And Harvoni For Treatment Of Chronic Hepatitis C
Monday, 24 Sep 2018 

Sept 24 (Reuters) - Gilead Sciences ::GILEAD SUBSIDIARY TO LAUNCH AUTHORIZED GENERICS OF EPCLUSA® (SOFOSBUVIR/VELPATASVIR) AND HARVONI® (LEDIPASVIR/SOFOSBUVIR) FOR THE TREATMENT OF CHRONIC HEPATITIS C.GILEAD SCIENCES INC - LIST PRICE OF AUTHORIZED GENERICS TO REFLECT DISCOUNTS IN SYSTEM TODAY.GILEAD SCIENCES - AUTHORIZED GENERICS WILL LAUNCH AT LIST PRICE OF $24,000 FOR MOST COMMON COURSE OF THERAPY AND WILL BE AVAILABLE IN JANUARY 2019.GILEAD SCIENCES INC - CONTINUING TO PURSUE COLLABORATIONS AND LONG-TERM FINANCING MODELS, SUCH AS A POTENTIAL SUBSCRIPTION MODEL.  Full Article

Allogene Therapeutics Files For IPO Of Up To $100 Million
Friday, 14 Sep 2018 

Sept 14 (Reuters) - Allogene Therapeutics::ALLOGENE THERAPEUTICS INC FILES FOR IPO OF UP TO $100 MILLION – SEC FILING.SAYS IT INTENDS TO APPLY TO HAVE ITS COMMON STOCK LISTED ON NASDAQ GLOBAL SELECT MARKET UNDER THE SYMBOL "ALLO".SAYS GOLDMAN SACHS & CO. LLC, J.P. MORGAN, COWEN ARE AMONG UNDERWRITERS TO IPO.SAYS JEFFERIES IS AMONG UNDERWRITERS TO IPO.PROPOSED IPO PRICE IS AN ESTIMATE SOLELY FOR CALCULATING SEC REGISTRATION FEE.SAYS PFIZER INC HAS 24.6 PERCENT HOLDING IN CO BEFORE THE IPO - SEC FILING.SAYS GILEAD SCIENCES INC HAS 8.4 PERCENT HOLDING IN CO BEFORE IPO.  Full Article

Gilead Sciences And Precision Biosciences Collaborate to Develop Hepatitis B Therapies
Wednesday, 12 Sep 2018 

Sept 12 (Reuters) - Gilead Sciences Inc ::GILEAD SCIENCES AND PRECISION BIOSCIENCES ANNOUNCE COLLABORATION TO DEVELOP THERAPIES AGAINST HEPATITIS B VIRUS USING ARCUS GENOME EDITING.GILEAD SCIENCES INC - PRECISION WILL BE PRIMARILY RESPONSIBLE FOR DEVELOPMENT, FORMULATION, AND PRECLINICAL EVALUATION OF INVESTIGATIONAL NUCLEASES.GILEAD SCIENCES INC - GILEAD WILL BE RESPONSIBLE FOR CLINICAL DEVELOPMENT AND COMMERCIALIZATION OF POTENTIAL THERAPIES.GILEAD SCIENCES INC - GILEAD WILL FULLY FUND RESEARCH AND DEVELOPMENT UNDER COLLABORATION.GILEAD SCIENCES INC - PRECISION IS ELIGIBLE TO RECEIVE MILESTONE PAYMENTS OF UP TO AN AGGREGATE OF $445 MILLION.  Full Article

REFILE-Lilly eyes more cancer deals, but wary of CAR-T, gene therapy

Jan 11 Eli Lilly and Co remains in the hunt for cancer drugs even after announcing an $8 billion purchase of Loxo Oncology this week, but it plans to remain on the sidelines when it comes to two of the hottest areas of drug development.